Prognostic parameter in CLL
Sample: DNA or 1 ml of EDTA bone marrow or blood
Assay: lymphotrack NGS kit (Invivoscribe)
Frequency: 1x/month
Version date: 26/09/2017
Accredited:

Commercial assay: IgH Somatic Hypermutation Assay, InVivoScribe Technologies.

BELAC accreditation number: 128-MED
Accredited:

SAMPLE TYPE:
-Blood or bone marrow (1ml, EDTA)
-Biopsy (fresh or FFPE)
TRANSPORT: room temperature
FREQUENCY: 1x/week
TEST TYPE: PCR & Sequencing, in house method from van Dongen et al,Leukemia, 2003, Biomed-2
BELAC Accreditation number 275-MED
Version date: 25/05/2021
Accredited:

SAMPLE TYPE: Peripheral blood or bone marrow (EDTA, 1-2 mL); biopsy (fresh)
TRANSPORT: room temperature, within 24h after sampling
FREQUENCY: upon request; max TAT: 5 weeks
TEST TYPE: Massive Parallel Sequencing (LymphoTrack SHM kit; INVIVOSCRIBE - CE IVD)
BELAC accreditation number 650-MED
Version date: 04/10/2021

SAMPLE TYPE:
-Blood or bone marrow
-Biopsy
FREQUENCY: on request
TEST TYPE: in house method VH-Leader (or Biomed FR1) PCR amplification followed by sequencing (ERIC recommendations)
Version date: 05/12/2017
Accredited:

sample type:bone marrow ro EDTA blood
frequency:once a week

Sample type: blood / bone marrow (EDTA, 2-5 ml)
Frequency: 1x/week
Test type: PCR on DNA (can also be performed on RNA), based on Aubin et al, Leukemia 1995 and Campbell et al, Molecular Immunology 1992.
BELAC accreditation number 215-MED
Accredited:

VH-family leader and FR1 primer PCR + Sanger sequencing
Version date: 24/10/2019
Accredited: